Alan Fuhrman

CIK: 0001303521

Transaction Breakdown

Open Market Buys (P)1 (10.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)8 (80.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (10.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

TYRA

Tyra Biosciences, Inc.

Officer

SWTX

SpringWorks Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (10 total)

TYRA
Tyra Biosciences, Inc.
Sep 15, 2026
Award(A)
Direct
951 shares at avg. $9.13$9K
TYRA
Tyra Biosciences, Inc.
May 5, 2026
Award(A)
Direct
20K shares-
TYRA
Tyra Biosciences, Inc.
Mar 13, 2026
Award(A)
Direct
1.4K shares at avg. $9.13$13K
TYRA
Tyra Biosciences, Inc.
Sep 15, 2025
Award(A)
Direct
701 shares at avg. $9.13$6K
TYRA
Tyra Biosciences, Inc.
Aug 7, 2025
Award(A)
Stock Option (Right to Buy)
Direct
170K shares-
SWTX
SpringWorks Therapeutics, Inc.
Jul 1, 2025
Disposition(D)
Direct
24.7K shares-
SWTX
SpringWorks Therapeutics, Inc.
May 14, 2025
Award(A)
Direct
10.1K shares-
TYRA
Tyra Biosciences, Inc.
Mar 14, 2025
Award(A)
Direct
1.2K shares at avg. $9.78$12K
TYRA
Tyra Biosciences, Inc.
Oct 30, 2024
Purchase(P)
Direct
9.5K shares at avg. $16.00$152K
TYRA
Tyra Biosciences, Inc.
Sep 13, 2024
Award(A)
Direct
954 shares at avg. $12.48$12K

		Type	Shares	Price		Ownership
Sep 15, 2026	TYRA Tyra Biosciences, Inc.	Award(A)	951	$9.13	$8,682	Direct
May 5, 2026	TYRA Tyra Biosciences, Inc.	Award(A)	20,000	-	$0	Direct
Mar 13, 2026	TYRA Tyra Biosciences, Inc.	Award(A)	1,376	$9.13	$12,562	Direct
Sep 15, 2025	TYRA Tyra Biosciences, Inc.	Award(A)	701	$9.13	$6,399	Direct
Aug 7, 2025	TYRA Tyra Biosciences, Inc.	Award(A) Stock Option (Right to Buy)	170,000	-	-	Direct
Jul 1, 2025	SWTX SpringWorks Therapeutics, Inc.	Disposition(D)	24,727	-	-	Direct
May 14, 2025	SWTX SpringWorks Therapeutics, Inc.	Award(A)	10,060	-	-	Direct
Mar 14, 2025	TYRA Tyra Biosciences, Inc.	Award(A)	1,238	$9.78	$12,101	Direct
Oct 30, 2024	TYRA Tyra Biosciences, Inc.	Purchase(P)	9,500	$16.00	$151,954	Direct
Sep 13, 2024	TYRA Tyra Biosciences, Inc.	Award(A)	954	$12.48	$11,904	Direct

1-10 of 10 transactions

About Fuhrman Alan

Fuhrman Alan (SEC CIK 0001303521) files insider reports with the SEC as Chief Financial Officer of Tyra Biosciences, Inc. (TYRA) and Director of SpringWorks Therapeutics, Inc. (SWTX).

Signal8 holds 10 ownership filings by Fuhrman Alan, all Form 4s, filed between Sep 17, 2024 and Sep 17, 2026. Those filings report 10 transactions, from Sep 13, 2024 to Sep 15, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Fuhrman Alan's filings is in CARLSBAD, CA.

Recent filings by Fuhrman Alan

Sep 15, 2026: Grant or award of TYRA shares (Form 4, code A).
May 5, 2026: Grant or award of TYRA shares (Form 4, code A).
Mar 13, 2026: Grant or award of TYRA shares (Form 4, code A).
Sep 15, 2025: Grant or award of TYRA shares (Form 4, code A).
Aug 7, 2025: Grant or award of TYRA derivative securities (Form 4, code A).

Other insiders filing for Tyra Biosciences, Inc. (TYRA)

Harris Todd, President and CEO
Rueb Yuliya, Vice President, Finance (PAO)
RA CAPITAL MANAGEMENT, L.P., Director
Verjee Rehan, Director
Moran Susan, Director
Simson Jake, Director

How to read Form 4 transaction codes